Erasca, Inc.

Equities

ERAS

US29479A1088

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
1.79 USD 0.00% Intraday chart for Erasca, Inc. -15.17% -15.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Powell Awaited -2- DJ
Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating MT
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Erasca, Inc. announced that it expects to receive $45 million in funding CI
Capital One Initiates Erasca at Overweight Rating With $8 Price Target MT
Erasca Enters Two Supply Deals With Novartis for Trametinib MT
Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials CI
North American Morning Briefing : Boeing Drags -2- DJ
Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma CI
ErascaCEO Bought Shares Worth $1,696,179, According to a Recent SEC Filing MT
HC Wainwright Cuts Erasca Price Target to $8 From $10, Maintains Buy Rating MT
Erasca Completes Dose Escalation in Phase 1 Thunderbbolt-1 Trial; Extends Cash Runway to 2026 MT
Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway CI
Erasca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HC Wainwright Initiates Erasca at Buy Rating With $10 Price Target MT
Erasca Shares Jump After CEO Stock Purchase Disclosed MT
Erasca Insider Bought Shares Worth $2,026,000, According to a Recent SEC Filing MT
Erasca Doses First Patient in Trial Assessing Naporafenib Plus Trametinib in Patients With RAS Q61X Solid Tumors MT
Erasca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell 3000E Index CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell Microcap Index CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell Microcap Value Index CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell 3000E Value Index CI
Erasca's Eras-801 for Treatment of Brain Tumors Gets FDA Orphan Drug Designation DJ
Chart Erasca, Inc.
More charts
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.79 USD
Average target price
7 USD
Spread / Average Target
+291.06%
Consensus
  1. Stock Market
  2. Equities
  3. ERAS Stock
  4. News Erasca, Inc.
  5. Erasca Enters Two Supply Deals With Novartis for Trametinib